Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

NCT00057525 is registered in ClinicalTrials.gov with DynPort Vaccine Company LLC, A GDIT Company as lead sponsor.

NCT NCT00057525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00057525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2003
Completion date
August 31, 2004
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anthrax